Cyberknife treatment for low and intermediate risk prostate cancer - Abstract

Cyberknife is an emerging treatment for early stage prostate cancer.

Between October 2012 and January 2014, 32 patients were treated in our institution. Prescribed dose was 35-36.25 Gy in five fractions. Biochemical response was observed in 22 patients. Four patients experienced G2 acute genitourinary toxicity and in two cases we recorded G3 acute GU toxicity. 5 patients experienced G2 acute proctitis. At last follow up visit, all patients were still alive. 29 remained free of disease at last follow up appointment, while three developed a biochemical recurrence. Our experience confirms the efficacy and safety of Cyberknife for localized prostate cancer.

Written by:
Detti B, Bonomo P, Masi L, Doro R, Cipressi S, Iermano C, Bonucci I, Franceschini D, Di Cataldo V, Di Brina L, Baki M, Simontacchi G, Meattini I, Carini M, Serni S, Nicita G, Livi L.   Are you the author?
Radiotherapy Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Italy.

Reference: Cancer Invest. 2015 Apr 1. Epub ahead of print.
doi: 10.3109/07357907.2015.1019679

PubMed Abstract
PMID: 25831274 Prostate Cancer Section